<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01179919</url>
  </required_header>
  <id_info>
    <org_study_id>10-002</org_study_id>
    <nct_id>NCT01179919</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects</brief_title>
  <official_title>Oseltamivir and Oseltamivir Carboxylate Pharmacokinetics in Obese Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manjunath Prakash Pai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One in three Americans are obese. Obese subjects may or may not need higher doses of the
      anti-flu drug known as Tamiflu (oseltamivir). The current study is being done to see if the
      FDA approved dose of oseltamivir will achieve similar concentrations in obese healthy
      volunteers compared to that previously shown in non-obese volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of obesity has increased dramatically over the past two decades in the United
      States (US). Twenty-five percent of adult Americans are now classified as obese. Obesity is
      associated with physiological alterations that can affect drug clearance and volume of
      distribution. Obese subjects are often excluded from phase 1 pharmacokinetic studies. As a
      result, drug dosing regimens developed for clinical use may not be appropriate for the obese
      population. Use of fixed dosing regimens may result in under dosing of obese patients. In
      contrast adjustment of drug dosing based on total body weight may lead to over dosing of
      obese patients. Oseltamivir phosphate (Tamiflu®) is an antiviral agent that is currently
      dosed as 75 mg once daily for chemoprophylaxis and twice daily for treatment of influenza in
      adults.

      Oseltamivir is rapidly converted to its active metabolite, oseltamivir carboxylate by
      esterases. The clearance of oseltamivir carboxylate is dependent on tubular secretion and
      glomerular filtration. Given that these drug elimination pathways may be enhanced in obese
      individuals, oseltamivir carboxylate plasma exposures may be lower in obese subjects compared
      to normal weight subjects. Although a specific plasma exposure target for oseltamivir
      carboxylate has not been established, lower oseltamivir carboxylate exposures may predispose
      obese patients to treatment failure and increase the probability for emergence of
      oseltamivir-resistant influenza virus. The current study proposes to characterize the plasma
      oseltamivir carboxylate concentration-time profile after multiple doses of oral oseltamivir
      in a cohort of healthy morbidly obese subjects. The study will be performed using a phase 1,
      open-label,multiple dose, pharmacokinetic study design in twenty obese adult subjects. This
      pilot study will provide pharmacokinetic data that may be incorporated into existing
      oseltamivir carboxylate population pharmacokinetic models to define appropriate doses of
      oseltamivir in obese patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steady-State AUC of Oseltamivir Carboxylate</measure>
    <time_frame>6 days</time_frame>
    <description>AUC is the area under the concentration-time curve. This is measured as concentration in nanograms of oseltamivir carboxylate per milliliter of plasma multiplied by time in hours (hour*ng/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Steady-State Cmax and Cmin of Oseltamivir Carboxylate</measure>
    <time_frame>6 days</time_frame>
    <description>Cmax is the maximum concentration and Cmin in the minimum concentration of oseltamivir carboxylate measured in nanogram of oseltamivir carboxylate per milliliter of plasma (ng/mL)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Oseltamivir Dosed Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oseltamivir 75 mg by mouth every 12 hours for 9 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>Capsule, 75 mg by mouth for 9 doses</description>
    <arm_group_label>Oseltamivir Dosed Group</arm_group_label>
    <other_name>Tamiflu</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males and females, 18 to 50 years of age

          -  non-smoking or light-smoking (≤5 cigarettes per day) volunteers

          -  BMI ≥ 40 kg/m2

          -  female subjects of childbearing potential either surgically sterilized, using an
             effective method of contraception (diaphragm, cervical cap,condom) or agree to abstain
             from sex from time of pre-study screening, during entire study period and 1 week
             following the study period.

        Exclusion Criteria:

          -  history of significant hypersensitivity reaction to oseltamivir

          -  history of gastric bypass surgical procedure

          -  history of significant clinical illness requiring pharmacological management

          -  abnormal serum electrolyte or complete blood count requiring further clinical work-up

          -  transaminases (AST or ALT) &gt;2.5 x upper limit of normal

          -  estimated creatinine clearance &lt;50 mL/min (Cockcroft-Gault equation)

          -  positive urine pregnancy test (if female)

          -  abnormal electrocardiogram (ECG) as judged by study physician

          -  unable to tolerate venipuncture and multiple blood draws

          -  clinically significant abnormal physical examination defined as a physical finding
             requiring further clinical work-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manjunath Pai, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ACPHS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TKL Research</name>
      <address>
        <city>Paramaus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2010</study_first_posted>
  <results_first_submitted>October 11, 2016</results_first_submitted>
  <results_first_submitted_qc>October 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 6, 2016</results_first_posted>
  <last_update_submitted>December 16, 2016</last_update_submitted>
  <last_update_submitted_qc>December 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Manjunath Prakash Pai</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Oseltamivir</keyword>
  <keyword>Obesity</keyword>
  <keyword>Influenza</keyword>
  <keyword>Pharmacokinetics in Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The summative data have been published and are available as open-access to the public: doi10.1128/AAC.00422-11</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oseltamivir Dosed Group</title>
          <description>Oseltamivir 75 mg by mouth every 12 hours for 9 doses
Oseltamivir: Capsule, 75 mg by mouth for 9 doses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects administered at least 1 dose of oseltamivir</population>
      <group_list>
        <group group_id="B1">
          <title>Oseltamivir Dosed Group</title>
          <description>Oseltamivir 75 mg by mouth every 12 hours for 9 doses
Oseltamivir: Capsule, 75 mg by mouth for 9 doses</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" lower_limit="19" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.7" lower_limit="40.0" upper_limit="54.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Steady-State AUC of Oseltamivir Carboxylate</title>
        <description>AUC is the area under the concentration-time curve. This is measured as concentration in nanograms of oseltamivir carboxylate per milliliter of plasma multiplied by time in hours (hour*ng/mL)</description>
        <time_frame>6 days</time_frame>
        <population>Subjects who received all 9 doses of oseltamivir</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir Dosed Group</title>
            <description>Oseltamivir 75 mg by mouth every 12 hours for 9 doses
Oseltamivir: Capsule, 75 mg by mouth for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Steady-State AUC of Oseltamivir Carboxylate</title>
          <description>AUC is the area under the concentration-time curve. This is measured as concentration in nanograms of oseltamivir carboxylate per milliliter of plasma multiplied by time in hours (hour*ng/mL)</description>
          <population>Subjects who received all 9 doses of oseltamivir</population>
          <units>hour*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2579" spread="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steady-State Cmax and Cmin of Oseltamivir Carboxylate</title>
        <description>Cmax is the maximum concentration and Cmin in the minimum concentration of oseltamivir carboxylate measured in nanogram of oseltamivir carboxylate per milliliter of plasma (ng/mL)</description>
        <time_frame>6 days</time_frame>
        <population>Subjects who received all 9 doses of oseltamivir</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir Dosed Group</title>
            <description>Oseltamivir 75 mg by mouth every 12 hours for 9 doses
Oseltamivir: Capsule, 75 mg by mouth for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Steady-State Cmax and Cmin of Oseltamivir Carboxylate</title>
          <description>Cmax is the maximum concentration and Cmin in the minimum concentration of oseltamivir carboxylate measured in nanogram of oseltamivir carboxylate per milliliter of plasma (ng/mL)</description>
          <population>Subjects who received all 9 doses of oseltamivir</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316" spread="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113" spread="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oseltamivir Dosed Group</title>
          <description>Oseltamivir 75 mg by mouth every 12 hours for 9 doses
Oseltamivir: Capsule, 75 mg by mouth for 9 doses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study only evaluated obese subjects. The concentrations measured in plasma may not reflect concentrations in tissues such as the lungs.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Manjunath Pai</name_or_title>
      <organization>University of Michigan</organization>
      <phone>7346473466</phone>
      <email>amitpai@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

